SYNOVETIN OA® has a dual mode of action1,2—
Reduces synovitis for long-term results
The active agent of Synovetin OA® is Tin-117m, a unique conversion electron therapeutic veterinary device3
Microparticles of Synovetin OA® are suspended in an injectable colloidal suspension.
When injected into the joint, these microparticles selectively target the macrophage source of inflammatory mediators through dual cellular targeting (macrophages, activated synoviocytes)1,2
View the dual cellular targeting of Synovetin OA® in action in the video.
Synovetin OA® redefines conservative management of chronic OA— transforming the treatment approach with 1 minimally-invasive procedure that provides safety and long-term efficacy.2
Synovetin OA® provides targeted, non-systemic therapy.1
Synovetin OA® answers a significant unmet need.
- Donecker JM, Stevenson NR. Radiosynoviorthesis: A new therapeutic and diagnostic tool for canine joint inflammation. Technical Bulletin. Exubrion Therapeutics, Inc. July 2019.
- Data on File, Exubrion Therapeutics.
- Fox SM, Donecker JM. Synovitis. Technical Bulletin. Exubrion Therapeutics, July 2019.